Connect to Cure
With its clinical-stage platform technology, Synaffix has established itself as the preferred technology provider enabling best-in-class targeted cancer therapeutics.
Connect to Innovate
Centered entirely around the antibody glycan, Synaffix has established a simple, rapidly deployable technology platform, enabling any company with an antibody to develop a proprietary, best-in-class ADC or bispecific.
Connect to Partner
Under a focused technology out-licensing business model, Synaffix has delivered multiple best-in-class therapeutic candidates for our partners’ pipelines.
Next-Generation ADCs Being Developed Under License Agreements
Partner
Preclinical
Phase 1
Partner / Licensee
in collaboration with Mersana Therapeutics, Inc.
Preclinical
Phase 1
Multiple Undisclosed
Partner / Licensee
Preclinical
Phase 1
MRG004A (TF-targeting)
Undisclosed
Partner / Licensee
Preclinical
Phase 1
IBI-343 (Claudin 18.2 targeting)
Undisclosed
Partner / Licensee
Preclinical
Phase 1
2x Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
3x Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
